**Background:** Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive bile acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, leading to elevated cholestanol and bile alcohols. Symptoms include chronic early-onset diarrhea, bilateral cataracts, tendon xanthomas, and progressive neurological deterioration. Diagnosis is often delayed due to varied symptomology and rarity, with patients waiting an average of 25 years from symptom onset to diagnosis. The accepted treatment is chenodeoxycholic acid (CDCA), which reduces cholestanol and bile alcohol levels and improves symptoms. This paper aims to provide patient and caregiver perspectives on living with CTX, alongside expert responses to address their concerns.
**Methods:** Patients and caregivers provided written accounts of their experiences, including symptom onset, time to diagnosis, treatments, and areas for improvement. Informed consent was obtained, and pseudonyms were used for those unwilling to disclose identity. The expert perspective was contributed by CTX researchers and physicians, including those performing genetic and biochemical testing. No new studies with human participants or animals were performed; this is a compilation of patient narratives and expert commentary.
**Key Results:** Four caregivers and one patient provided accounts. Caregiver 1 described her daughter diagnosed at age 8 after 18 months of seeking diagnosis, with symptoms including tremor, ataxia, peripheral neuropathy, and brain fog; her son was diagnosed later after his sister's diagnosis. Both children started CDCA 125 mg three times daily, with cholestanol levels normalized in the daughter after 3 months, while the son required taking CDCA with food to lower levels. After 6 months, improvements included less brain fog, improved tremors, and ataxia. However, the daughter still has autonomic dysfunction, learning disabilities, peripheral neuropathy, and anxiety; the son has autistic-like behaviors, OCD, anxiety, and depression. Both had cataracts removed 1 year after starting treatment. Caregiver 2 reported her child diagnosed as a teenager after over 10 years of symptoms, including Asperger's syndrome diagnosis, nonverbal learning disorder, and later elevated triglycerides and metabolic waste products. After CDCA treatment, cognitive symptoms improved and cholestanol normalized, but osteopenia persists. Caregiver 3 described her husband diagnosed at age 32 after over 10 years of tendon xanthomas, balance issues, and misdiagnoses of multiple sclerosis and Stiff Man Syndrome. He receives CDCA 200 mg four times daily, with improved mental clarity but worsened gait and persistent xanthomas; cholestanol levels remain slightly elevated despite maximum dose. Caregiver 4 reported her sister diagnosed at age 35 after over 15 years of symptoms including bilateral juvenile cataracts, cognitive impairment, and mood disorders; treatment with CDCA 250 mg three times daily led to stabilization but irreversible neurocognitive impairment. Patient 1, diagnosed at age 27 after bilateral cataracts at 19 and xanthoma at 26, started CDCA 250 mg three times daily, which helped diarrhea and normalized cholestanol; she still has small xanthomas and occasional balance issues. Expert perspective notes that diagnostic delay is common, with CTX often misdiagnosed as autism spectrum disorder (ASD) or multiple sclerosis. A study of 77 CTX patients identified 10 with ASD, 9 of whom were pediatric. Bilateral cataracts occur in up to 88% of CTX patients, with prevalence of CTX in early-onset bilateral cataracts being 1 in 100, compared to general population prevalence of 1 in 44,000–3,400,000. Newborn screening has been nominated for inclusion on the Recommended Uniform Screening Panel, but requires prospective evidence. Biochemical testing (blood cholestanol and urine bile alcohols) is available at only three US laboratories; after treatment, testing is typically every 6–12 months. Online resources include CTX Alliance and United Leukodystrophy Foundation (ULF).
**Clinical Implications:** The patient and caregiver accounts underscore the profound impact of diagnostic delay on outcomes, with irreversible neurological damage occurring before treatment initiation. Early diagnosis through newborn screening or targeted testing in at-risk populations (e.g., those with early-onset bilateral cataracts or tendon xanthomas with normal lipids) is critical. CDCA treatment improves symptoms but does not reverse established damage, highlighting the need for prompt therapy. The expert perspective emphasizes that pediatricians, dermatologists, cardiologists, and endocrinologists should consider CTX in patients with tendon xanthomas and normal blood lipids. The lack of accessible biochemical testing and inconsistent monitoring guidelines pose challenges; standardized protocols for follow-up are needed. The CTX community would benefit from increased psychiatric support, online resources, and opportunities for patient and family connection. Advocacy groups like CTX Alliance and ULF provide valuable information and support. Overall, this paper calls for greater awareness, earlier diagnosis, and comprehensive care for CTX patients.